IRTC
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
iRhythm Technologies, Inc.
- Nom
- iRhythm Technologies, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $4.0B
- Employés
- 2,400
- PDG
- Quentin S. Blackford
- Site web
- https://www.irhythmtech.com
- Marché
- ATRCBEATBSXHSCSKMTSLIVN
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 26 859 titres (~3 348 011,95 $ US)
- Insiders
- Blackford Quentin S.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$7,428,764
Avg sell (VWAP, 90d window) $124.38 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | Wilson Daniel G. | Sell · S | 773 | $121.83 | $94,175 | Form 4 |
| 2026-08-10 | Blackford Quentin S. | Sell · S | 26,859 | $124.65 | $3,348,012 | Form 4 |
| 2026-08-10 | Murphy Patrick Michael | Sell · S | 7,093 | $124.65 | $884,156 | Form 4 |
| 2026-08-10 | Patterson Chad | Sell · S | 7,093 | $124.65 | $884,170 | Form 4 |
| 2026-08-10 | Shrishrimal Sumi | Sell · S | 5,372 | $124.65 | $669,641 | Form 4 |
| 2026-08-10 | Turakhia Minang | Sell · S | 7,093 | $124.65 | $884,151 | Form 4 |
| 2026-08-03 | Patterson Chad | Sell · S | 2,712 | $122.12 | $331,192 | Form 4 |
| 2026-08-03 | Rodda Julianne | Sell · S | 2,112 | $122.12 | $257,919 | Form 4 |
| 2026-08-03 | Smith Mervin | Sell · S | 617 | $122.12 | $75,349 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
IRTC presents a compelling event-driven setup with a confirmed acquisition of VitalConnect, a strong Q2 earnings beat (+20.1% revenue growth), and a raised 2026 outlook, all supporting a catalyst score of 75 with solid…
The first sentence of the analysis written for IRTC on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.63 · operating margin -4.9% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 70.6% | 68.9% | 67.3% | 68.5% | 66.2% | |
| Ebit Margin | -4.1% | -16.9% | -24.2% | -27.2% | -30.9% | |
| Ebitda Margin | -0.5% | -12.5% | -19.7% | -22.4% | -25.8% | |
| Operating Profit Margin | -4.9% | -19.5% | -25.4% | -27.7% | -31.0% | |
| Pretax Profit Margin | -5.8% | -19.0% | -24.9% | -28.2% | -31.3% | |
| Continuous Operations Profit Margin | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% | |
| Net Profit Margin | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% | |
| Bottom Line Profit Margin | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% | |
| Current Ratio | 4.627 | 5.822 | 2.150 | 3.241 | 3.478 | |
| Quick Ratio | 4.484 | 5.696 | 2.020 | 3.071 | 3.361 | |
| Solvency Ratio | -0.021 | -0.104 | -0.454 | -0.463 | -0.462 | |
| Cash Ratio | 1.554 | 3.783 | 0.337 | 0.885 | 1.452 | |
| Price To Earnings Ratio | -127.655 | -24.840 | -26.495 | -24.142 | -34.014 | |
| Price To Earnings Growth Ratio | 2.069 | 2.448 | -6.425 | -1.989 | -0.286 | |
| Forward Price To Earnings Growth Ratio | 2.069 | 2.448 | -6.425 | -1.989 | -0.286 | |
| Price To Earnings Diluted Ratio | -127.655 | -24.840 | -26.495 | -24.142 | -34.014 | |
| Price To Earnings Diluted Growth Ratio | 2.069 | 2.448 | -6.425 | -1.989 | -0.286 | |
| Price To Book Ratio | 37.178 | 30.943 | 15.553 | 11.685 | 12.350 | |
| Price To Sales Ratio | 7.601 | 4.753 | 6.633 | 6.819 | 10.693 | |
| Price To Free Cash Flow Ratio | 164.502 | -61.752 | -36.097 | -53.030 | -52.446 | |
| Price To Operating Cash Flow Ratio | 70.227 | 829.777 | -65.223 | -121.771 | -91.436 | |
| Debt To Assets Ratio | 0.717 | 0.791 | 0.300 | 0.292 | 0.254 | |
| Debt To Equity Ratio | 4.787 | 8.106 | 0.618 | 0.546 | 0.421 | |
| Debt To Capital Ratio | 0.827 | 0.890 | 0.382 | 0.353 | 0.296 | |
| Long Term Debt To Capital Ratio | 0.810 | 0.877 | 0.143 | 0.127 | 0.034 | |
| Financial Leverage Ratio | 6.678 | 10.246 | 2.062 | 1.869 | 1.656 | |
| Working Capital Turnover Ratio | 1.376 | 1.798 | 3.050 | 1.969 | 1.219 | |
| Operating Cash Flow Ratio | 0.532 | 0.031 | -0.467 | -0.258 | -0.430 | |
| Operating Cash Flow Sales Ratio | 0.108 | 0.006 | -0.102 | -0.056 | -0.117 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.427 | -13.437 | 1.807 | 2.296 | 1.743 | |
| Debt Service Coverage Ratio | -0.374 | -5.826 | -26.743 | -22.332 | -6.513 | |
| Interest Coverage Ratio | -2.798 | -9.009 | -34.291 | -27.497 | -85.494 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -3.236 | |
| Operating Cash Flow Coverage Ratio | 0.111 | 0.005 | -0.386 | -0.176 | -0.321 | |
| Capital Expenditure Coverage Ratio | 1.745 | 0.069 | -1.239 | -0.771 | -1.345 | |
| Dividend Paid And Capex Coverage Ratio | 1.745 | 0.069 | -1.239 | -0.771 | -1.345 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1,557.115 | -42.229 | -34.703 | -30.979 | -41.356 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 70.6% | ▲1.7% | ▲2.3% |
| Ebit Margin | -4.1% | ▲12.8% | ▲16.6% |
| Ebitda Margin | -0.5% | ▲12.0% | ▲15.7% |
| Operating Profit Margin | -4.9% | ▲14.6% | ▲16.8% |
| Pretax Profit Margin | -5.8% | ▲13.2% | ▲16.0% |
| Continuous Operations Profit Margin | -6.0% | ▲13.2% | ▲16.0% |
| Net Profit Margin | -6.0% | ▲13.2% | ▲16.0% |
| Bottom Line Profit Margin | -6.0% | ▲13.2% | ▲16.0% |
| Current Ratio | 4.627 | ▼-1.196 | ▲0.763 |
| Quick Ratio | 4.484 | ▼-1.211 | ▲0.758 |
| Solvency Ratio | -0.021 | ▲0.083 | ▲0.280 |
| Cash Ratio | 1.554 | ▼-2.229 | ▼-0.048 |
| Price To Earnings Ratio | -127.655 | ▼-102.814 | ▼-80.225 |
| Price To Earnings Growth Ratio | 2.069 | ▼-0.379 | ▲2.905 |
| Forward Price To Earnings Growth Ratio | 2.069 | ▼-0.379 | ▲2.905 |
| Price To Earnings Diluted Ratio | -127.655 | ▼-102.814 | ▼-80.225 |
| Price To Earnings Diluted Growth Ratio | 2.069 | ▼-0.379 | ▲2.905 |
| Price To Book Ratio | 37.178 | ▲6.235 | ▲15.636 |
| Price To Sales Ratio | 7.601 | ▲2.848 | ▲0.301 |
| Price To Free Cash Flow Ratio | 164.502 | ▲226.255 | ▲172.267 |
| Price To Operating Cash Flow Ratio | 70.227 | ▼-759.549 | ▼-54.088 |
| Debt To Assets Ratio | 0.717 | ▼-0.074 | ▲0.246 |
| Debt To Equity Ratio | 4.787 | ▼-3.319 | ▲1.891 |
| Debt To Capital Ratio | 0.827 | ▼-0.063 | ▲0.277 |
| Long Term Debt To Capital Ratio | 0.810 | ▼-0.067 | ▲0.412 |
| Financial Leverage Ratio | 6.678 | ▼-3.568 | ▲2.176 |
| Working Capital Turnover Ratio | 1.376 | ▼-0.422 | ▼-0.506 |
| Operating Cash Flow Ratio | 0.532 | ▲0.502 | ▲0.651 |
| Operating Cash Flow Sales Ratio | 0.108 | ▲0.102 | ▲0.140 |
| Free Cash Flow Operating Cash Flow Ratio | 0.427 | ▲13.864 | ▲1.860 |
| Debt Service Coverage Ratio | -0.374 | ▲5.452 | ▲11.983 |
| Interest Coverage Ratio | -2.798 | ▲6.211 | ▲29.020 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲0.647 |
| Operating Cash Flow Coverage Ratio | 0.111 | ▲0.106 | ▲0.264 |
| Capital Expenditure Coverage Ratio | 1.745 | ▲1.676 | ▲2.053 |
| Dividend Paid And Capex Coverage Ratio | 1.745 | ▲1.676 | ▲2.053 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1557.115 | ▼-1514.886 | ▼-1215.839 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $5.68B | $2.81B | $3.27B | $2.80B | $3.45B | |
| Enterprise value | $6.17B | $3.13B | $3.36B | $2.85B | $3.44B | |
| EV / Sales | 8.26x | 5.29x | 6.82x | 6.95x | 10.66x | |
| EV / Op. cash flow | 76.35x | 923.38x | -67.09x | -124.04x | -91.17x | |
| EV / Free cash flow | 178.85x | -68.72x | -37.13x | -54.02x | -52.30x | |
| EV / EBITDA | -1557.12x | -42.23x | -34.70x | -30.98x | -41.36x | |
| Net debt / EBITDA | -124.89x | -4.28x | -0.97x | -0.57x | 0.12x | |
| Current ratio | 4.63x | 5.82x | 2.15x | 3.24x | 3.48x | |
| Income quality | -1.81x | -0.03x | 0.41x | 0.20x | 0.37x | |
| Graham net-net | -$7 | -$8 | -$1 | $2 | $3 | |
| Tax burden | 102.2% | 100.5% | 100.6% | 100.2% | 100.4% | |
| Interest burden | 143.2% | 112.8% | 103.1% | 103.7% | 101.2% | |
| Working capital | $550.9M | $534.9M | $123.4M | $199.7M | $217.7M | |
| Invested capital | $745.2M | $708.4M | $277.7M | $336.9M | $359.1M | |
| Return on assets | -4.4% | -12.2% | -28.5% | -25.9% | -21.9% | |
| Operating ROA | -3.8% | -16.9% | -28.4% | -25.0% | -20.5% | |
| Return on tangible assets | -4.4% | -12.2% | -28.5% | -26.0% | -21.9% | |
| Return on equity | -29.2% | -124.6% | -58.7% | -48.4% | -36.3% | |
| Return on invested capital | -4.2% | -13.8% | -36.7% | -30.6% | -25.1% | |
| Return on capital employed | -4.2% | -14.1% | -38.4% | -31.7% | -26.6% | |
| Earnings yield | -0.8% | -4.0% | -3.8% | -4.1% | -2.9% | |
| Free cash flow yield | 0.6% | -1.6% | -2.8% | -1.9% | -1.9% | |
| Capex / Op. cash flow | 57.3% | 1443.7% | -80.7% | -129.6% | -74.3% | |
| Capex / Depreciation | 175.0% | 189.9% | 182.6% | 152.1% | 169.1% | |
| Capex / Sales | 6.2% | 8.3% | 8.2% | 7.3% | 8.7% | |
| SG&A / Sales | 64.2% | 70.7% | 78.3% | 78.4% | 85.1% | |
| R&D / Sales | 11.3% | 17.5% | 12.2% | 11.3% | 12.0% | |
| Stock comp / Sales | 11.8% | 12.8% | 15.7% | 14.1% | 16.9% | |
| Intangibles / Total assets | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | |
| Days sales outstanding | 37d | 49d | 46d | 44d | 52d | |
| Days payables outstanding | 4d | 14d | 13d | 21d | 35d | |
| Operating cycle | 73d | 77d | 77d | 87d | 87d | |
| Cash conversion cycle | 69d | 63d | 65d | 66d | 52d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-14 iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform IRTC''s VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
- 2026-08-14 Here''s Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-08-12 iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE Bank of America Corp DE trimmed its holdings in iRhythm Technologies (NASDAQ: IRTC) by 41.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 432,539 shares of the company''s stock after selling 309,231 shares during the period. Bank of America Corp DE owned approximately 1.32% of
- 2026-08-10 iRhythm Q2 Earnings Beat Estimates on Volume Growth, ''26 View Raised IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
- 2026-08-08 Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 8, 202
- 2026-08-08 Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm NEW YORK, Aug. 8, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) 聽breached their fiduciary duties to shareholders.聽 According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
- 2026-08-07 iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.
- 2026-08-07 iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
- 2026-08-06 iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago.
- 2026-08-06 iRhythm Technologies Q2 Earnings Call Highlights iRhythm Technologies NASDAQ: IRTC reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.